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Background:Drug eluting balloon (DEB) is a new therapeutic option for treatment of obstructive coronary lesions
in percutaneous coronary intervention (PCI). There is limited data on the safety and efﬁcacy of DEB in Asian
patients in contemporary clinical registries. We evaluated the clinical efﬁcacy and safety of SeQuent Please
paclitaxel-eluting balloon in our cohort of South-East Asian patients in real world clinical practice.
Methods: Between January 2010 to November 2012, 320 patients (76%male,mean age 61.3 ± 11.2 years) with a
total of 337 coronary lesionswere treatedwith SeQuent Please drug-eluting balloon (DEB). The primary endpoint
was major adverse cardiac events (MACE) ie a composite of cardiovascular death, target vessel related myocar-
dial infarction (MI) and target lesion revascularization (TLR) at 9 months follow-up.
Results: Themajority of patients presentedwith acute coronary syndrome (76%).Themost common indication for
the use of DEB was small vessel disease (54%) followed by instent restenosis (21%), bifurcation lesions (6%) and
others (19%). An average of 1.23 ± 0.5 DEB were used per patient, with mean DEB diameter of 2.6 ± 0.6 mm
and average total length of 24.0 ± 11.1 mm.
At 9 months follow-up, 5.3% of patients developed MACE. MACE was mainly driven by TLR(4%) followed by
target vessel related myocardial infarction (2.6%) and cardiovascular death (1%).
Conclusion: SeQuent Please DEB was a safe and effective treatment modality in our cohort of South-East Asian
patients with a low incidence of MACE observed at 9 months follow-up.© 2013 The Authors. Published by Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Drug-eluting balloon [1] (DEB) has emerged as a new therapeutic
option to treat obstructive coronary artery disease (CAD) in percutane-
ous coronary intervention (PCI). Non-stent-based local drug delivery
using DEB has several advantages as it:
1) inhibits excessive neointimal hyperplasia following balloon angio-
plasty of a diseased native coronary artery without leaving a
permanent metallic frame
2) avoid a “stent-in-stent” approach in previously stented arteriests of interest.
eliability and freedom from bias
an Tock SengHospital, 11, Jalan
ax: +65 6357 7772.
land Ltd. Open access under CC BY-NC3) eliminate the risk of stent thrombosis
4) reduce the duration of dual anti-platelet therapy (DAPT).
The clinical efﬁcacy of DEB has beenwell proven in randomized con-
trolled trials [2,3] in the treatment of baremetal stent instent restenosis
( BMS ISR)when compared to uncoated balloon/paclitaxel-coated stent
with sustainable results [4] observed at long term follow-up. Favourable
results are also seen with the use of DEB in drug-eluting stent (DES) ISR
[5,6] although robust data is lacking for the combined use of DEB and
BMS [7,8] in routine PCI and also in speciﬁc lesions subsets [9–11] like
small vessel, bifurcation lesion, etc. Similar to DES, DEB has been used
in “off-label” indications in the “real world” and there is limited data
[12] on its clinical efﬁcacy and safety in Asian patients in contemporary
clinical registries. We therefore sought to evaluate the clinical efﬁcacy
and safety of SeQuent Please DEB (B. Braun, Melsungen, Germany) in
our cohort of South-East Asian patients in “real world” clinical practice.
2. Materials and Methods
2.1. Study Population
From January 2010 to November 2012, a total of 320 symptomatic patients with na-
tive coronary lesions, instent restenosis (ISR) and saphenous venous graft lesions (total
of 337 lesions) were treated with SeQuent Please DEB at our institution.-ND license.
Table 1
Baseline Clinical Characteristics of Patients.
N = 320
Mean age (years) 61.3 ± 11.2
Male:Female,n, % 242: 78 (76 : 24)
Ever smokers,n,% 173 (54.1)
Diabetes,n, % 155 (48.4)
Hyperlipidemia,n,% 261 (81.6)
Hypertension,n,% 257 (80.3)
Previous myocardial infarction,n,% 102 (32.0)
Previous PCI,n,% 137 (42.8)
Previous CABG,n,% 24 (7.5)
LVEF(%) 45 ± 13
Presentation:
STEMI,n,% 48 (15)
NSTEMI/UAP,n,% 194 (61)
Stable angina,n,% 78 (24)
*PCI denotes percutaneous coronary intervention, CABG coronary artery bypass graft,
LVEF left ventricular ejection fraction, STEMI ST elevation myocardial infaction,
NSTEMI/UAP denotes non STEMI/unstable angina pectoris.
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All PCIs were performed using standard techniques and according to contemporary
practice guidelines. All patients were treated with aspirin 100 mg prior to the procedure
and indeﬁnitely thereafter. Patients also received clopidogrel ( an oral loading dose of
600 mg followed by 75 mg daily) before the procedure, followed by a minimum of
1 month in patients who received DEB alone and a minimum of 3 months in patients
who received BMS implantation in combination with DEB. Additional duration of
clopidogrel treatment was at the discretion of the attending physician.
2.3. Use of DEB during PCI
The SeQuent Please DEB catheter was loaded with paclitaxel 3 ug/mm2. The
length of the DEB catheter was chosen to exceed the target lesion for at least
2 mm ( at both proximal and distal ends). The catheter(s) was inﬂated for 30 to
60 s with a minimum of 7 atm. Predilation of the diseased coronary segment
with a uncoated balloon/scoring balloon/cutting balloon before the use of DEB
was encouraged. BMS was implanted if the angiographic result after DEB alone
therapy was not satisfactory due to signiﬁcant recoil/residual stenosis or dissection
(Type C-F). For those opting for the combined use of DEB and BMS as primary ther-
apy, the length of DEB had to exceed the length of the implanted BMS ( this prin-
ciple was also applied for bail-out stenting).
2.4. End-Points and Deﬁnitions
The primary end-point was major adverse cardiac event (MACE) ie a composite of car-
diovascular (CVS) death, target vessel relatedmyocardial infarction (MI) and target lesion re-
vascularization (TLR) at 9 months follow-up. Secondary end-points include individual
components of MACE and target lesion thrombosis.
Death from CVS causes was deﬁned as death due to acute MI, cardiac perforation or
tamponade, arrhythmia, a complication of the PCI procedure or as any death in which a
CVS cause could not be ruled out.
Target-vessel relatedMIwas deﬁned as the presence of newQwaves in at least 2 con-
tiguous leads on electrocardiogram (concordantwith the intervened target lesion)with el-
evation in cardiac troponin or in creatine kinase/creatine kinase-MB above the upper limit
of the normal range, or in the absence of pathologic Qwaves, MIwas diagnosed in the pres-
ence of an elevation in cardiac troponin or in creatine kinase N 2 times the upper limit of
normal. TLRwas deﬁned as any repeat revascularization (percutaneous or surgical) second-
ary to a stenosis N 50% within the stent or within 5 mm proximal or distal to the stented
segment. Target lesion thrombosis was deﬁned according to the Academic Research Con-
sortium [13] criteria for deﬁnite andprobable stent thrombosis. In our study,wedeﬁnedna-
tive coronary artery as small vessel when reference vessel diameter ≤ 2.8 mm and as de
novo lesion when reference vessel diameter N 2.8 mm. Our retrospective study conforms
to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the
institution's human research committee.
2.5. Statistical analysis
Continuous variables were expressed as mean ± standard error of mean. Dichot-
omous variables were expressed as counts and percentages. Statistical comparisons
were performed using Student’s t test or Fisher’s exact test, as appropriate. Multivar-
iate regression analysis was performed ( using an enter regression model) to evalu-
ate predisposing factors for TLR, in which each entered variable had p value b 0.1
based on univariate analysis. Calculations were performed using SPSS software (ver-
sion 16.0; SPSS, Inc., Chicago, Illinois). All p-values were 2-sided and p-values b 0.05
were considered statistically signiﬁcant.
3. Results
Table 1 show the baseline clinical characteristics of the study patients.
Themean age of the patients at presentationwas 61.3 ± 11.2 years with
male preponderance (76%).
Diabetesmellitus (DM)was present in 155 patients (48.4%) and 137
patients (43%) had history of prior stenting. The mean left ventricular
function was 45 ± 13 %. The majority (76%) of patients presented
with acute coronary syndrome (ACS).
Table 2 shows the angiographic features and procedural data of our
patients. The majority of patients (78 %) had multi-vessel disease on
coronary angiography. The most common target vessel for PCI with
DEB was left anterior descending artery (37%), right coronary artery
(18%), left circumﬂex artery (17%) and others (28%). “Others” include
side branches ( mostly diagonals followed by posterior descending ar-
teries/posterior left ventricular branches, obtusemarginals), saphenous
venous grafts ( all seven cases involved distal venous graft anastomosis)
and left main lesions (2 patients).Glycoprotein IIb/IIIa inhibitors were administered in 232 patients
(73%). The most common indication for the use of DEB in our registry
was small vessel disease (54%) followed by ISR (21%), bifurcation le-
sions (6%), de novo lesions (5%) and others (14%). Of the 72 ISR, DEB in-
tervention was performed for 56% BMS ISR and 44% DES ISR. Based on
Mehran classiﬁcation for ISR, DEBwas largely used for focal ISR (Mehran
type I: 56%) followed by Mehran type II (28%), Mehran Type IV (12%)
and Mehran Type III (4%).
DEB alone therapywas the predominant approach (82% of patients )
during PCIwhereasDEB followed by baremetal stentingwas performed
for the remaining 18% of patients. An average of 1.23 ± 0.5 DEB were
used per patient, with mean DEB diameter of 2.6 ± 0.6 mm and aver-
age total length of 24.0 ± 11.1 mm.
For the initial 320 patients, 5 patients died during index hospitaliza-
tion and 11patientswere lost to follow-up. Table 3 summarizes the clin-
ical outcomes of 304 patients at 9 months follow-up. A total of 16
patients (5.3%) developed MACE at 9 months follow-up.
MACEwasmainly driven by TLR (4%) followed by target vessel related
MI (2.6%) andCVSdeath (1%). Therewas no reported target lesion throm-
bosis. Factors associated with TLR by univariate analysis ( TLR group vs
non-TLR group) were older age at presentation (67.2 ± 11.2 years vs
60.6 ± 10.9 years, p = 0.04), diabetes mellitus (75% vs 47%, p = 0.07),
DES ISR (25% versus 8.6%, p = 0.08), DEB alone therapy during PCI
(58.3% vs 83%, p = 0.04), mean number of DEB per patient (1.5 ± 0.67
vs 1.23 ± 0.47, p = 0.06) and total DEB length (31.7 ± 14.6 vs
23.9 ± 11 mm, p = 0.02). However no independent predictors of TLR
were identiﬁed by multi-variable analysis. Figs. 1 to 7 illustrates our
clinical experiences with the use of DEB in “real world”clinical practice.
4. Discussion
To our knowledge, this is the largest registry in the South-East Asian
region evaluating the use of DEB in an all-comer group of patients in the
“real world”. We found that the use of SeQuent Please DEB was a safe
and effective treatment modality for South-East Asian patients in the
“real world” setting. The intermediate term clinical outcomes in our co-
hort of patients were good with a low incidence of MACE.
In recent years, DEB has emerged as a viable therapeutic option for
treating CAD as the current DES technology [14] has limitations like
late stent thrombosis and prolonged DAPT.
Paclitaxel is the drug of choice for all the commercially available DEB
manufacturers because of its highly lipophilic properties which allows
rapid diffusion into the vessel wall and sustained anti-proliferative
effect despite its short contact with the vessel wall. The largest clinical
evidence [2–9,11,12] has been reported for DEB coated with
paclitaxel-iopromide with N 3000 patients evaluated in randomized
Table 2
Baseline Angiographic Features and Procedural Data of Patients.
N = 320
No.of obstructive coronary artery:
1,n,% 70 (22)
2,n,% 112 (35)
3,n,% 138 (43)
Target vessel:
LAD,n,% 124 (37)
RCA,n,% 62 (18)
LCx,n,% 58 (17)
Others,n,% 93 (28)
Lesion type:
Small vessel,n,% 182 (54)
ISR,n,% 72 (21)
Bifurcation,n,% 20 (6)
De novo,n,% 17 (5)
Others,n,% 46 (14)
PCI Approach:
DEB alone therapy ,n,% 276 (82)
DEB and bare metal stenting,n,% 61 (18)
Mean number of DEB per patient 1.2 ± 0.5
Mean diameter of DEB, mm 2.6 ± 0.6
Total length of DEB (average),mm 24.0 ± 11.1
Glycoprotein IIb/IIIa inhibitors,n,% 232 (72)
* LAD denotes left anterior descending, RCA right coronary artery, LCx left circumﬂex,
ISR instent restenosis, DEB drug-eluting balloon.
Fig. 1. Baseline angiography showing diffuse lesion in mid to distal LAD artery.
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gy [15] (ESC) guidelines have given a Class IIa approval to DEB for the
treatment of BMS ISR as there is robust clinical data [2–4] supporting
its use in this particular lesion subset. Favourable results are also seen
with the use of DEB in DES ISR [5,6] although robust data is lacking for
the combined use of DEB and BMS [7,8] in routine PCI and also in specif-
ic lesions subsets [9–11] like small vessel, diffuse disease, bifurcation
lesion, calciﬁed lesion, thrombus-containing lesion, chronic total occlu-
sion, etc. Similar to DES, DEB has been used in “off-label” indications and
our study is one of the few [12] to evaluate its clinical efﬁcacy and safety
in the “realworld”. The clinical proﬁle of patients in the “realworld” set-
ting are usually different from those recruited into clinical trials as they
often have more complex lesions and certain clinical issues which ne-
cessitate a shorter DAPT regimen.
In our registry, the majority of our patients (76%) presented with
acute coronary syndrome and the percentage of patients with DM
(48.4%) was quite high. Small vessel disease (often with concomitant
diffuse disease) was a common feature of our patients on coronary an-
giography and accounted for the predominant use of DEB (54%) in our
registry. Our patients’ clinical characteristics were very different from
patients enrolled in the SeQuent Please World Wide Registry [12]
which had a small number of Asian patients. For the latter registry, the
majority of patients (73%) received treatment with SeQuent Please
DEB for BMS/DES ISR and the percentage of patients with DM (36%)
was much lower. By comparing the mean number of DEB per patient,
mean DEB diameter and average total length of DEB (1.23 ± 0.5,
2.6 ± 0.6 mm and 24.0 ± 11.1 mm) in our registry and the
SeQuent Please World Wide Registry registry (1.1 DEBs per lesion,Table 3
Clinical Outcomes at 9 months Follow-up.
N = 304
MACE,n,%, 16(5.3)
Cardiovascular death,n,% 3 (1)
TLR,%,n 12 (4)
Target vessel related MI,n,% 8 (2.6)
Target lesion thrombosis,n,% 0 (0)
MACE denotes major adverse cardiac events, TLR target lesion revascu-
larization, MI myocardial infarction2.9 ± 0.4 mm and 20.3 ± 5.5 mm), we can infer that our South-East
Asian patients had a relatively higher proportion of small vessel and dif-
fuse CAD than their non-Asian counterparts. This could be due to the
higher prevalence of DM in our cohort of patients.
DEBmaybe a good alternative option for diffuse lesions as outcomes
remain relatively unfavorable for stent-based coronary intervention es-
pecially those with de novo long CAD. Even in the DES era, studies
[16–18] have shown that the TLR rates can range from 6% to 28% for
such lesion subset with higher rates of ISR for paclitaxel DES. A recent
study [19] evaluating the full metal jacket use of overlapping
everolimus-eluting stents in extra long lesion (N60 mm) reported an
angiographic restenosis of 12.5% at 9 months and a high cardiac death
rate at long term follow-up ( possibly related to stent thrombosis).
In our study, DEB alone therapy (82%) was the predominant ap-
proach for PCI. This is the preferred PCI strategy as recommended by
the German DEB Consensus Group [20] as this approach is associated
with a low late loss (which translates into lower rate of TLR). Adequate
lesion preparation before application of DEB to culprit lesion is impor-
tant and we used scoring/cutting balloons in addition to uncoated bal-
loon in approximately 30% of all PCI cases. DEB followed by bare metal
stenting was performed for the remaining 18% of cases. This strategy
was used as primary therapy (75%) or as bail-out stenting (25%) inFig. 2. Final angiographic result of mid to distal LAD ( after treatment with DEB alone
therapy).
Fig. 3. Baseline angiography showing a critical trifurcation stenosis in distal LCx artery
( lesion site highlighted by small arrowhead NN).
Fig. 5. Baseline angiography showing a diffuse obstructive lesion in proximal to mid RCA
which was also moderately calciﬁed.
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(Type C-F) after deﬂation of DEB.
In our study, a total of 16patients (5.3%) developedMACEat 9 months
follow-up and it was mainly driven by TLR (12 patients). Although the
number was small, we identiﬁed certain clinical features/factors that
were predictive of TLR by univariate analysis. These included older age
at presention, longer length of DEB and lower use of DEB alone therapy
(p b 0.05). There was a trend towards higher rate of TLR when patients
have history of DM and underlying DES ISR. This is consistent with the
ﬁndings of the SeQuent Please World Wide Registry registry [12] which
had shown unfavourable DEB results in patients with DM versus non-
diabetics and similarly, in DES ISR versus BMS ISR. In our study, 5 patients
who were treated with combined DEB and bare metal stenting required
re-intervention. All ﬁve have long stents implanted ( average total stent
length of 37.2 ± 15.3 mm) which likely contributed to its restenosis be-
sides underlying diabetes mellitus which was present in 4 patients. 3 of
the patients were also found to havemoderate to heavily calciﬁed vessels
(Figs. 5–7). For calciﬁed lesions, DEB may not be suitable as the distribu-
tion of paclitaxel during balloon inﬂation may not be homogenous and
the drug diffusion into the vessel wall may be suboptimal. The coating
of DEB may also be “damaged” during balloon delivery if the coronaryFig. 4. Final angiographic result of distal LCx artery ( after treatment with DEB alone
therapy).segment proximal to target lesion is calciﬁed as a result of friction and
resistance.
5. Limitation
There were several limitations to our study. All patients in our study
received treatment with SeQuent Please DEB and our results could only
be extrapolated to those who had received similar therapy. Whether
similar results would be seen with patients receiving other types of
DEB is unknown as not all DEBs are equal in terms of clinical efﬁcacy.
Furthermore, our study was a single center registry, subject to selection
and operator bias.
There is also lack of routine angiographic follow-up in our study
which may lead to overestimation of its purported clinical beneﬁt in
the “real world”. As many of our treated patients had small vessel dis-
ease, they may have developed clinically silent restenosis/occlusion
and therefore assumed to be ﬁne on follow-up.
6. Conclusion
We found that theuse of SeQuent PleaseDEBwas a safe and effective
treatment modality for South-East Asian patients in the “real world”Fig. 6. Final angiographic result of RCA after treatment with DEB and bare metal stenting.
Fig. 7. Relook angiogram at 5 months showing focal ISR in mid RCA.
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tients were good with low incidence of MACE. Longer clinical follow-
up is necessary to establish its true clinical efﬁcacy and safety.References
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